: The effect of curcumin supplementation as adjunctive therapy in the treatment of patients with bipolardisorder-Depression

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231206060281N1

Enrollment

Registered

2023-12-14

Start date

2023-12-16

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar disorder

Interventions

Intervention 1: Intervention group: In addition to the previous usual drugs (sodium valproate and risperidone or olanzapine or ketamine), they will receive 2 tablets of curcumin 500 mg daily for 6 wee

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Consent of the patient or the patient's guardian to participate in the study Diagnosing a patient's bipolar depression disorder by a psychiatrist based on V-DSM criteria Age over 18 years

Exclusion criteria

Exclusion criteria: Other psychiatric disorders Chronic inflammatory diseases Taking herbal medicines History of allergy to herbal medicines and turmeric Pregnancy or breastfeeding Patients taking anticoagulant and antiplatelet drugs such as aspirin, clopidogrel, heparin, enoxaparin, warfarin

Design outcomes

Primary

Measure	Time frame
The effectiveness of the treatment is the main outcome of this study that will be measured with the questionnaire. The questionnaire will be completed for patients before and after the intervention. The difference in the questionnaire score will be considered the treatment effect. Timepoint: The beginning and end of the study. Method of measurement: the Persian Version of Bipolar Depression Rating Scale.	—

Measure

Time frame

The effectiveness of the treatment is the main outcome of this study that will be measured with the questionnaire. The questionnaire will be completed for patients before and after the intervention. The difference in the questionnaire score will be considered the treatment effect. Timepoint: The beginning and end of the study. Method of measurement: the Persian Version of Bipolar Depression Rating Scale.

—

Secondary

Measure	Time frame
Measurement of drug side effects. Timepoint: End of week 6 and 12. In order for the doctor to ensure that the conditions of all patients are the same and to control the effects of treatment with standard drugs, all patients will receive the usual standard treatment for 6 weeks. Then, before dividing the patients into two groups and starting the intervention, the questionnaire will be completed by the assistant psychiatrist. Then the patients will be randomly divided into two groups and will receive the assigned treatment for 6 weeks. The questionnaire will be completed again for them. Method of measurement: Standard questionnaire.	—

Measure

Time frame

Measurement of drug side effects. Timepoint: End of week 6 and 12. In order for the doctor to ensure that the conditions of all patients are the same and to control the effects of treatment with standard drugs, all patients will receive the usual standard treatment for 6 weeks. Then, before dividing the patients into two groups and starting the intervention, the questionnaire will be completed by the assistant psychiatrist. Then the patients will be randomly divided into two groups and will receive the assigned treatment for 6 weeks. The questionnaire will be completed again for them. Method of measurement: Standard questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Azadeh Maqsoodlou Rad

Gorgan University of Medical Sciences

azadeh_rad1990@yahoo.com+98 17 3245 1660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026